These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 35669431)

  • 21. Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer.
    Hestetun KE; Rosenlund NB; Stanisavljević L; Dahl O; Myklebust MP
    Front Oncol; 2022; 12():853545. PubMed ID: 36110945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tn Antigen Expression Defines an Immune Cold Subset of Mismatch-Repair Deficient Colorectal Cancer.
    Matsumoto T; Okayama H; Nakajima S; Saito K; Nakano H; Endo E; Kase K; Ito M; Yamauchi N; Yamada L; Kanke Y; Onozawa H; Fujita S; Sakamoto W; Saito M; Saze Z; Momma T; Mimura K; Kono K
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
    Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
    Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival.
    Sorrentino C; D'Antonio L; Fieni C; Ciummo SL; Di Carlo E
    Front Immunol; 2021; 12():778329. PubMed ID: 34975867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ASCL2 induces an immune excluded microenvironment by activating cancer-associated fibroblasts in microsatellite stable colorectal cancer.
    Zhang D; Ni QQ; Liang QY; He LL; Qiu BW; Zhang LJ; Mou TY; Le CC; Huang Y; Li TT; Wang SY; Ding YQ; Jiao HL; Ye YP
    Oncogene; 2023 Sep; 42(38):2841-2853. PubMed ID: 37591954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer.
    Chen QY; Chen YX; Han QY; Zhang JG; Zhou WJ; Zhang X; Ye YH; Yan WH; Lin A
    Front Immunol; 2021; 12():679090. PubMed ID: 34054869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-L1 Expression in Colorectal Carcinoma Correlates with the Immune Microenvironment.
    Shahin M; Patra S; Purkait S; Kar M; Das Majumdar SK; Mishra TS; Samal SC; Nayak HK
    J Gastrointest Cancer; 2024 Jun; 55(2):940-949. PubMed ID: 38530597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A TGFβ-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer.
    Endo E; Okayama H; Saito K; Nakajima S; Yamada L; Ujiie D; Kase K; Fujita S; Endo H; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
    Mol Cancer Res; 2020 Sep; 18(9):1402-1413. PubMed ID: 32493700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Microenvironment Characteristics of Urachal Carcinoma and Its Implications for Prognosis and Immunotherapy.
    Zhang X; Wang S; Nie RC; Qu C; Chen J; Yang Y; Cai M
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relationship of KRAS expression with KRAS status, prognosis, and tumor-infiltrated T lymphocytes in colorectal cancer.
    Zhou Y; Zeng Z; Li Z; Ruan L; Xie H; Ye F; Huang L; Liu H; Kang L
    Therap Adv Gastroenterol; 2024; 17():17562848241249387. PubMed ID: 38757097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.
    Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A
    Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair-deficient, Advanced Colorectal Carcinomas.
    Saberzadeh-Ardestani B; Graham RP; McMahon S; Ahanonu E; Shi Q; Williams C; Hubbard A; Zhang W; Muranyi A; Yan D; Jin Z; Shanmugam K; Sinicrope FA
    Clin Cancer Res; 2023 Oct; 29(20):4268-4277. PubMed ID: 37566222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma.
    Wang Z; Wang X; Xu Y; Li J; Zhang X; Peng Z; Hu Y; Zhao X; Dong K; Zhang B; Gao C; Zhao X; Chen H; Cai J; Bai Y; Sun Y; Shen L
    BMC Med; 2022 Apr; 20(1):133. PubMed ID: 35443723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
    Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
    Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low PD-1 Expression in Cytotoxic CD8
    Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
    Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
    [No Abstract]   [Full Text] [Related]  

  • 40. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
    El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
    J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.